key: cord-0939218-8mbw8rt8 authors: Alvarez-Garcia, Jesus; Lee, Samuel; Gupta, Arjun; Cagliostro, Matthew; Joshi, Aditya A.; Rivas-Lasarte, Mercedes; Contreras, Johanna; Mitter, Sumeet S.; LaRocca, Gina; Tlachi, Pilar; Brunjes, Danielle; Glicksberg, Benjamin S.; Levin, Matthew A.; Nadkarni, Girish; Fayad, Zahi; Fuster, Valentin; Mancini, Donna; Lala, Anuradha title: Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19 date: 2020-10-28 journal: J Am Coll Cardiol DOI: 10.1016/j.jacc.2020.09.549 sha: 06c0839a193ee219c1e11094a0819af8fd3b56b5 doc_id: 939218 cord_uid: 8mbw8rt8 BACKGROUND: Patients with pre-existing heart failure (HF) are likely at higher risk for adverse outcomes in coronavirus disease-2019 (COVID-19), but data on this population are sparse. OBJECTIVES: This study described the clinical profile and associated outcomes among patients with HF hospitalized with COVID-19. METHODS: This study conducted a retrospective analysis of 6,439 patients admitted for COVID-19 at 1 of 5 Mount Sinai Health System hospitals in New York City between February 27 and June 26, 2020. Clinical characteristics and outcomes (length of stay, need for intensive care unit, mechanical ventilation, and in-hospital mortality) were captured from electronic health records. For patients identified as having a history of HF by International Classification of Diseases-9th and/or 10th Revisions codes, manual chart abstraction informed etiology, functional class, and left ventricular ejection fraction (LVEF). RESULTS: Mean age was 63.5 years, and 45% were women. Compared with patients without HF, those with previous HF experienced longer length of stay (8 days vs. 6 days; p < 0.001), increased risk of mechanical ventilation (22.8% vs. 11.9%; adjusted odds ratio: 3.64; 95% confidence interval: 2.56 to 5.16; p < 0.001), and mortality (40.0% vs. 24.9%; adjusted odds ratio: 1.88; 95% confidence interval: 1.27 to 2.78; p = 0.002). Outcomes among patients with HF were similar, regardless of LVEF or renin-angiotensin-aldosterone inhibitor use. CONCLUSIONS: History of HF was associated with higher risk of mechanical ventilation and mortality among patients hospitalized for COVID-19, regardless of LVEF. C oronavirus disease-2019 (COVID- 19) , caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is a rapidly expanding pandemic associated with overwhelming morbidity and mortality across the globe (1). History of cardiovascular disease has repeatedly been associated with worse prognosis (2, 3) , whereas de novo cardiovascular involvement in its various forms, from myocardial injury to myocarditis and shock, has also been amply described (4) (5) (6) (7) . Among patients hospitalized with COVID-19, patients with heart failure (HF) represent a population at the highest potential risk for complications due to a high prevalence of underlying frailty or renal dysfunction among other comorbidities (8) . Yet data as to the clinical course and outcomes of COVID-19 among patients with a history of HF are scarce (9) (10) (11) (12) . Furthermore, it is unknown as Table 1 ). Interestingly, 14 (17.5%) presented with worsening LVEF of $10 points. De novo severe tricuspid and mitral regurgitation was encountered in 9 (11.3%), and 6 (7.5%) patients, respectively, in comparison with the study before admission. Other cardiovascular tests such as cardiac computed tomography and left or right heart catheterization were performed rarely on a case-by-case basis during the COVID-19 hospitalization ( RAASi were independently associated with worse prognosis ( Table 3) . Remarkably, race was not associated with worse outcomes. Values are mean AE SD, n (%), or median (interquartile range). *N ¼ 2,264. †In those patients without previous anticoagulation. ALT ¼ alanine transaminase; BMI ¼ body mass index; BNP ¼ brain natriuretic peptide; BP ¼ blood pressure; BUN ¼ blood urea nitrogen; CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease; CRP ¼ C-reactive protein; ECG ¼ electrocardiogram; HF ¼ heart failure; ICU ¼ intensive care unit; INR ¼ international normalized ratio; LOS ¼ length of stay; MRA ¼ mineraloid receptor antagonist; OSA ¼ obstructive sleep apnea; RAAS ¼ renin-angiotensin-aldosterone system; rpm ¼ respirations per minute; WBC ¼ white blood cells. Alvarez-Garcia et al. replication in the myocardium on autopsy (23) . Widespread inflammation, as well as increased microand macrovascular thrombosis, may underlie the cardiac manifestations of arrhythmias, myocarditis, and de novo LV dysfunction that have been reported (20, 22 After a multivariable logistic regression adjusting for age, sex, race, obesity, hypertension, diabetes, coronary artery disease, atrial fibrillation, chronic kidney disease, chronic obstructive pulmonary disease, previous treatment with renin-angiotensin-aldosterone inhibitors, systolic blood pressure, heart rate, oxygen saturation, white blood count, lymphocytes, creatinine, and albumin on admission, history of HF persisted as an independent risk factor for the need for intensive care unit (ICU) care, intubation and mechanical ventilation, and in-hospital mortality. CI ¼ confidence interval; OR ¼ odds ratio; other abbreviations as in Figure 1 . Alvarez-Garcia et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection Takotsubo cardiomyopathy in COVID-19 COVID-19 and cardiac arrhythmias The variety of cardiovascular presentations of COVID-19 Considerations for heart failure care during the COVID-19 pandemic Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy Incidence of new-onset and worsening heart failure before and after the COVID-19 epidemic lockdown in Denmark: a nationwide cohort study Heart failure in the time of COVID-19 Reninangiotensin-aldosterone system inhibitors in patients with Covid-19 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Statistical Analysis with Missing Data Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology Decreases in acute heart failure hospitalizations during COVID Reductions in heart failure hospitalizations during the COVID-19 pandemic Changes in care delivery for patients with heart failure during the COVID-19 pandemic: results of a multicenter survey The impact of COVID-19 on heart failure hospitalization and management: report from a heart failure Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the Heart Failure Society of America Heart failure collaboratory statement on heart failure remote monitoring in the landscape of COVID-19 and social distancing Enforcement policy for non-invasive remote monitoring devices used to support patient monitoring during the coronavirus disease 2019 (COVID-19) public health emergency (Revised) Optimizing access to heart failure care in Canada during the COVID-19 pandemic Challenges in heart transplantation during COVID-19: a single center experience Dexamethasone in hospitalized patients with Covid-19 -preliminary report Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19 Inflammation in heart failure: JACC state-of-the-art review COVID-19, heart failure, left ventricular ejection fraction, outcome, renin-angiotensin-aldosterone system inhibitor APPENDIX For an expanded Methods section as well as supplemental figures and a table